-pro-
capromab
capromab pendetide
abituzumab
alfuzosin
conatumumab
-col-
prostein
tenatumomab
figitumumab
tigatuzumab
adecatumumab
duligotuzumab
naptumomab estafenatox
acrixolimab
-got-
inotuzumab
drozitumab
nofetumomab
avelumab
panitumumab
patritumab
sipuleucel-T
oleclumab
prostate-specific antigen
PSA blood test
onartuzumab
matuzumab
nacolomab tafenatox
lexatumumab
lintuzumab
dacetuzumab
oncopeptide
dulanermin
ramucirumab
mapatumumab
cixutumumab
dalotuzumab
etaracizumab
inotuzumab ozogamicin
prostatic adenocarcinoma
pamrevlumab
samalizumab
-tum-
prostate cancer
apolizumab
ertumaxomab
-mar-
catumaxomab
altumomab
sibrotuzumab
lucatumumab
labetuzumab
onapristone
immunocytokine
satumomab
cabazitaxel
bunazosin
teprotumumab
malignin
p53
antiprostate
tamsulosin
folliculin
cemiplimab
probasin
pemtumomab
arcitumomab
cantuzumab
votumumab
silodosin
immunokinase
durvalumab
carlumab
detumomab
pritumumab
blinatumomab
malignoma
apalutamide
minretumomab
volociximab
ensituximab
flutamide
bavituximab
taplitumomab
darolutamide
naxitamab
prostasphere
besilesomab
nilutamide
prostatosphere
prostate specific antigen
monospecific
edrecolomab
PSA
-les-
plasmacytoma
relatlimab
milatuzumab